Abstract
The aim of the work was to assess the quality of life in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate or methotrexate monotherapy. The statistically significant improvement of quality of life in both groups 12 months after onset of the treatment was roughly identical. Rutiximab was prescribed after ineffective treatment with TNF-α inhibitors.
Publication types
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived / pharmacology*
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / pharmacology*
-
Arthritis, Rheumatoid / drug therapy*
-
Drug Therapy, Combination
-
Humans
-
Methotrexate / administration & dosage
-
Methotrexate / pharmacology*
-
Middle Aged
-
Quality of Life / psychology*
-
Rituximab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Rituximab
-
Methotrexate